Middle East respiratory syndrome coronavirus, or MERS-CoV, is a virus that jumps sporadically from dromedary camels to people and can cause severe pneumonia with a case-fatality rate estimated at roughly 38%—far higher than most respiratory infections circulating today. First identified in Saudi Arabia in 2012, the virus has caused more than 2,600 confirmed cases across 27 countries, with the vast majority linked to the Arabian Peninsula. Despite a decade of research, there is still no licensed vaccine or proven antiviral for humans, which makes understanding how the virus spreads, whom it hits hardest, and how to avoid it all the more important.
Where the Virus Comes From
MERS-CoV is a zoonotic virus, meaning it originates in animals and occasionally crosses into humans. The primary reservoir is the dromedary camel. Epidemiological evidence and laboratory confirmation leave little doubt about that link: researchers have isolated the virus from sick camels and from the people who caught it from them, finding full genome sequences that were identical between a fatal human case and the camel the patient had been in close contact with.1PubMed. Evidence for camel-to-human transmission of MERS coronavirus Serologic testing in that case confirmed the virus was circulating among the camels before the human infection occurred.
Experimentally inoculated camels develop only mild disease—essentially a runny nose—but they shed large quantities of virus from the upper respiratory tract, making them efficient spreaders even when they look healthy.2Emerging Infectious Diseases. Replication and Shedding of MERS-CoV in Upper Respiratory Tract of Inoculated Dromedary Camels That subclinical presentation is one reason the virus persists in camel populations: herders may not realize their animals are infectious.
Farther back in evolutionary history, the virus likely traces to bats. Diverse coronaviruses closely related to MERS-CoV have been found in bat species around the world, some belonging to the same viral species.3PubMed Central. Bat origin of human coronaviruses The leading theory is that the virus circulated in bats, adapted to camels at some point in the past, and now uses camels as its main stepping stone to people. Direct bat-to-human transmission has not been documented for MERS-CoV.
How MERS-CoV Gets into Human Cells
Once the virus reaches human airways, it latches onto a protein on the surface of our cells called dipeptidyl peptidase 4, or DPP4. The virus’s spike glycoprotein contains a receptor-binding domain that fits into part of DPP4 like a key in a lock, and this interaction is what allows the virus to fuse with and enter the cell.4PubMed Central. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 DPP4 is found on cells in the lungs, kidneys, and intestines, which helps explain why MERS-CoV can affect multiple organs.
Small differences in DPP4 across species partly explain which animals are susceptible to the virus. Genetic variations in DPP4 among humans may also influence individual susceptibility. Research has shown that certain natural polymorphisms in the DPP4 gene can reduce the virus’s ability to enter cells.5PubMed Central. Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus That doesn’t mean some people are immune—just that the molecular fit between the virus and the receptor can vary from person to person in ways that may make infection slightly easier or harder to establish.
How MERS-CoV Spreads Between People
Current evidence supports a clear hierarchy of transmission routes. Direct contact with live dromedary camels is the primary way the virus enters human populations, and from there it occasionally spreads between people—mainly through close, unprotected contact with someone who is symptomatic. There is little evidence that camel products like milk or meat are a significant source of infection, and asymptomatic MERS cases do not appear to be major drivers of spread.6PubMed Central. Middle East Respiratory Syndrome Coronavirus Transmission
This is a crucial difference between MERS-CoV and the virus behind COVID-19. MERS-CoV has a basic reproduction number below one, meaning each case, on average, infects fewer than one additional person. Left to its own devices, any chain of human-to-human transmission tends to burn itself out. But that average conceals dramatic unevenness. Analysis of cluster sizes has revealed a substantial potential for superspreading events, where a single patient infects dozens or even over a hundred others, particularly in healthcare settings.7PubMed. The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission Hospitals are the main amplification point. Both MERS and SARS nosocomial outbreaks have been characterized by early super-spreading events, although the reproduction number typically drops below one within a few generations of transmission once infection-control measures kick in.8PubMed Central. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study
The virus is also reasonably tough outside the body. Lab studies showed that MERS-CoV remained recoverable on surfaces for more than 48 hours under cool, dry conditions (around 20°C and 40% relative humidity), and aerosolized virus showed no measurable drop in viability at the same temperature and humidity.9PubMed. Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions That environmental persistence raises the possibility that fomite transmission—picking up the virus from contaminated surfaces—plays a supporting role alongside respiratory droplets, especially in hospital wards and camel barns.
Symptoms and How the Disease Unfolds
After exposure, symptoms typically take about five to seven days to appear, though the incubation period can range from as short as two days to as long as 14 days.10PubMed Central. MERS-CoV as an emerging respiratory illness: A review of prevention methods Studies comparing outbreak data have noted some variation between settings: an analysis of cases in South Korea estimated a mean incubation period of about seven days, while Saudi Arabian cases averaged closer to five days.11Scientific Reports. Comparison of incubation period distribution of human infections with MERS-CoV in South Korea and Saudi Arabia Whether that reflects differences in viral dose, host factors, or reporting precision is unclear.
The clinical spectrum is wide. Some infected people have no symptoms at all, others develop a mild respiratory illness, and a significant fraction rapidly progress to severe pneumonia. Symptomatic patients commonly present with fever, chills, muscle aches, cough, and shortness of breath. Gastrointestinal symptoms—diarrhea, vomiting, and abdominal pain—appear in a notable subset, sometimes as the main complaint rather than a sidebar to the respiratory illness. Pneumonia is common at the time of initial presentation.10PubMed Central. MERS-CoV as an emerging respiratory illness: A review of prevention methods
In severe cases, the disease can spiral into multi-organ failure. Acute kidney injury is a particularly prominent complication of MERS. A case series of patients who developed kidney injury during severe MERS infection found that nearly all required critical care; the majority experienced the most severe grade of kidney damage, and the mortality rate among these patients was 70%.12PubMed Central. Acute Kidney Injury Associated with Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection Other serious complications in that group included septic shock, respiratory failure requiring mechanical ventilation, and secondary bacterial infections. The kidneys’ vulnerability likely relates to the high expression of DPP4 on kidney cells, giving the virus a direct route of attack beyond the lungs.
Who Is Most Vulnerable
MERS-CoV does not affect everyone equally. Older adults, people with chronic kidney disease, and people with diabetes are at significantly higher risk of developing severe illness and dying. Epidemiological studies from Saudi Arabia have consistently pointed to these three groups.13PubMed Central. Demographic, clinical, and outcomes of confirmed cases of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in Najran, Kingdom of Saudi Arabia (KSA)
Diabetes appears to be the single most important comorbidity. Research using animal models has shown that diabetes is not just a marker of frailty; it actively worsens the infection. Animals with the equivalent of type 2 diabetes had a dysregulated immune response to MERS-CoV, leading to more severe and prolonged lung damage compared with those without diabetes.14PubMed Central. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection In practical terms, the immune system in a diabetic host does not mount an effective early defense, and then overcorrects with damaging inflammation. That combination of sluggish viral clearance and excessive inflammation is what makes the disease so much more dangerous in this group.
Diagnosis
MERS-CoV is confirmed through molecular testing—specifically, real-time PCR that targets unique genetic sequences of the virus. The standard approach uses samples from the lower respiratory tract whenever possible, since virus concentrations tend to be higher there than in a simple nose or throat swab. Diagnostic kits amplify two distinct genomic targets, a region called upE and a gene called ORF1a, to confirm a positive result.15PubMed Central. Performance Evaluation of the PowerChek MERS (upE & ORF1a) Real-Time PCR Kit for the Detection of Middle East Respiratory Syndrome Coronavirus RNA The dual-target strategy reduces the chance of false positives. Because MERS remains uncommon outside endemic areas, public health authorities generally recommend testing only for patients with severe respiratory illness and a relevant travel or exposure history, not as routine screening.
Treatment Landscape
There is no approved antiviral for MERS-CoV, so treatment remains largely supportive—fluids, oxygen, mechanical ventilation when needed, and management of complications like kidney failure. That said, several drug candidates have shown promise in preclinical research.
Remdesivir, which later became well known during the COVID-19 pandemic, was studied against MERS-CoV in animal models before SARS-CoV-2 even existed. In macaques, preventive treatment with remdesivir given 24 hours before inoculation completely blocked clinical disease and strongly inhibited viral replication in the lungs. Even when given 12 hours after infection as a therapeutic treatment, the drug reduced lung damage and clinical severity.16PubMed Central. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
Head-to-head laboratory comparisons of candidate drugs found that remdesivir and interferon beta were far more potent against MERS-CoV in cell culture than lopinavir and ritonavir, an HIV drug combination that had been repurposed for testing. Adding ritonavir to lopinavir did not meaningfully improve antiviral activity.17Nature Communications. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV A clinical trial (the MIRACLE trial) evaluated lopinavir/ritonavir combined with interferon beta in human MERS patients in Saudi Arabia, but translating preclinical leads into proven therapies has been slowed by the sporadic nature of MERS outbreaks—you can’t run a large drug trial when cases trickle in a few at a time.
Prevention in the Hospital
Because hospitals have been the site of nearly every major MERS cluster, infection control in healthcare settings is a critical prevention strategy. Guidelines emphasize a layered approach: isolating suspected or confirmed cases in negative-pressure rooms when available, strict hand hygiene, use of personal protective equipment (gowns, gloves, N95 respirators, eye protection), and thorough disinfection and environmental cleaning.18PubMed Central. Middle East Respiratory Syndrome Infection Control and Prevention Guideline for Healthcare Facilities The experience of the 2015 South Korea outbreak, which spiraled from a single traveler returning from the Middle East into 186 cases across multiple hospitals, demonstrated how quickly things go wrong when triage and isolation protocols fail.
For the general public visiting the Arabian Peninsula—including the millions of pilgrims attending Hajj or Umrah each year—standard advice includes avoiding direct contact with camels, not drinking unpasteurized camel milk, and practicing careful hand hygiene. Modeling of the 2014 Hajj estimated that large numbers of cases were unlikely even under pessimistic assumptions, but monitoring remained important to detect any mass-infection events and minimize the risk of international spread.19PubMed Central. Estimating Potential Incidence of MERS-CoV Associated with Hajj Pilgrims to Saudi Arabia, 2014
The One Health Strategy and Camel Vaccines
One of the more pragmatic ideas for controlling MERS-CoV is to vaccinate the camels rather than waiting for a human vaccine. The logic is straightforward: if you stop the virus from circulating in its animal reservoir, you eliminate most of the opportunities for it to spill over into people. This “One Health” approach—treating animal and human disease as interconnected—is considered by many researchers to be the fastest and most cost-effective route to controlling MERS in the endemic region.20PubMed Central. Vaccines against Middle East respiratory syndrome coronavirus for humans and camels Camel vaccines face fewer regulatory hurdles, are cheaper to develop, and could theoretically be deployed across herds in the Arabian Peninsula in a mass-vaccination campaign.
Modeling work supports the idea. Simulations of MERS-CoV transmission in camel populations suggest that vaccinating calves alone—even with a vaccine that only reduced infectiousness rather than preventing infection entirely—could achieve large reductions in how often the virus jumps to people, and could interrupt transmission altogether in lower-risk settings provided coverage reached 70 to 90%.21PubMed Central. Modelling transmission of Middle East respiratory syndrome coronavirus in camel populations and the potential impact of animal vaccination Early-stage vaccine candidates for camelids have been tested, including a particle-display vaccine based on the virus’s receptor-binding domain that prevented transmission to one of three vaccinated llamas in a direct-contact challenge.22PubMed Central. Protective efficacy of an RBD-based Middle East respiratory syndrome coronavirus (MERS-CoV) particle vaccine in llamas That modest result in a small exploratory study still represents progress in a field where no licensed camel vaccine exists yet.
On the human side, several vaccine candidates have entered early clinical trials. A chimpanzee-adenovirus-vectored vaccine (ChAdOx1 MERS) was safe and provoked both antibody and T-cell responses in a phase 1 trial.23PubMed Central. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial A DNA-based vaccine (GLS-5300) became the first MERS vaccine to advance into human testing, and other platforms including modified vaccinia Ankara–vectored vaccines have followed.24The Lancet Infectious Diseases. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial A phase 1b trial of the MVA-MERS-S vaccine has also been conducted in individuals previously exposed to SARS-CoV-2, specifically to evaluate whether prior COVID-19 vaccination or infection interferes with the response to a MERS vaccine.25The Lancet Infectious Diseases. Safety and immunogenicity of the MVA-MERS-S vaccine against Middle East respiratory syndrome in individuals with previous exposure to SARS-CoV-2 None of these candidates has yet reached large-scale efficacy testing, again because the sporadic and geographically concentrated nature of MERS outbreaks makes traditional phase 3 trials extremely difficult to run.
How MERS-CoV Compares with COVID-19
People who lived through the COVID-19 pandemic understandably want to know how MERS-CoV stacks up. A comparative analysis of both viruses in Saudi Arabia provides some concrete numbers. The case-fatality rate for MERS-CoV was estimated at about 38%, compared with roughly 1.7% for COVID-19 during the wave studied.26Infectious Disease Modelling. A comparative analysis of epidemiological characteristics of MERS-CoV and SARS-CoV-2 in Saudi Arabia MERS is deadlier per case by a wide margin but spreads much less efficiently. Its serial interval—the time between successive cases in a chain of transmission—was about 14 days, nearly three times the five-day serial interval for COVID-19. That longer gap gives public health systems more time to detect and isolate cases before they spark new infections. Perhaps most critically, COVID-19’s serial interval was shorter than its incubation period, which means people were spreading the virus before they felt sick. At least three-quarters of COVID-19 transmission occurred before symptom onset. MERS-CoV does not appear to share that feature to the same degree, which helps explain why it has remained a regional threat rather than a global pandemic.
Long-Term Health Effects in Survivors
Surviving severe MERS does not mean a clean return to normal. A systematic review of long-term outcomes after hospitalization for MERS or SARS found that impaired lung function—specifically reduced gas-exchange capacity—persisted in more than a quarter of patients up to six months after discharge. Exercise capacity also remained below expected levels. Beyond physical recovery, the psychological toll was steep: roughly a third of survivors met criteria for depression, and nearly 40% showed signs of post-traumatic stress disorder in the months following their illness.27PubMed. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis
Data specific to MERS survivors in South Korea paints a similarly concerning picture. At 12 months after infection, about 43% of survivors had clinically significant PTSD, 27% had depression, and 28% reported insomnia. Over one in five showed at least moderate suicidal risk.28PubMed Central. Posttraumatic stress disorder and depression of survivors 12 months after the outbreak of Middle East respiratory syndrome in South Korea These figures are striking, and they underscore that the burden of MERS extends well beyond the acute illness. Chronic fatigue has also been flagged as a persistent problem, with follow-up research tracking MERS survivors over two years to examine links between chronic fatigue syndrome and suicidality during recovery.29PubMed Central. Association between chronic fatigue syndrome and suicidality among survivors of Middle East respiratory syndrome over a 2-year follow-up period
These long-term effects mirror what would later be documented in COVID-19 survivors under the label “long COVID,” and they reinforce a broader pattern: severe coronavirus infections can leave lasting footprints on the lungs, the brain, and mental health. For the relatively small but growing population of MERS survivors, access to rehabilitation, psychological support, and long-term monitoring remains an important and often underemphasized aspect of care.